Recent Reports and Perspectives on Chronic Lymphocytic Leukemia
Advertisement
Recent articles on developments and controversies in the treatment of chronic lymphocytic leukemia include the following features from The ASCO Post, which are also available at www.ascopost.com:
- “Recent FDA Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare B-Cell Lymphomas,” August 15, 2014
- “Ibrutinib Surpasses Ofatumumab as Second-Line Treatment of Chronic Lymphocytic Leukemia,” by Alice Goodman, June 25, 2014
- “Looking Ahead in Treating Chronic Lymphocytic Leukemia,” by Caroline Helwick, June 10, 2014
- “Ibrutinib for Previously Treated Chronic Lymphocytic Leukemia,” by Matthew Stenger, March 15, 2014
- “Encouraging Early Results With Novel Agents in CLL,” by Alice Goodman, March 1, 2014
- “First-Line Obinutuzumab/Chlorambucil Improves Outcomes Over Rituximab/Chlorambucil in Older CLL Patients With Comorbidities,” by Alice Goodman, March 1, 2014
- “Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia,” by Matthew Stenger,
December 1, 2013 - “High Rate of Durable Remissions With Ibrutinib in Patients With Relapsed Chronic Lymphocytic
Leukemia,” by Matthew Stenger, August 15, 2013 - “Potent Activity Shown for First-in-Class PI3K-delta Inhibitor in Chronic Lymphocytic Leukemia,” by Caroline Helwick, June 10, 2013
- “Ibrutinib CLL Trial: Where Is the Equipoise?” by Susan O’Brien, MD, May 1, 2013
- “The Ethical Imperative of Clinical Equipoise,” by Steven J. Schuster, MD, May 1, 2013
- “A Promising New Agent’s Road to Approval in CLL Raises Questions, Stirs Controversy,” by Ronald Piana, May 1, 2013 ■
Related Articles
Linking Biology and Therapy in Chronic Lymphocytic Leukemia
Recent discoveries in biology, therapy, and (most importantly) the interplay between these two have led to groundbreaking advances in chronic lymphocytic leukemia (CLL). These advances underline the impact of the “translational” approach to cancer management in general.
Standard of Care...